Tumor lysis syndrome is a potentially fatal oncologic emergency, extremely rare in
prostate cancer, with very few cases reported in the literature.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.Mol Clin Oncol. 2017; 6: 589-592
- Tumor lysis syndrome in solid tumors: an up to date review of the literature.Rare Tumors. 2014; 6: 68-76
- Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.Int J Urol. 2005; 12: 1012-1013
- Prevention and management of tumor lysis syndrome in adults with malignancy.J Adv Pract Oncol. 2013; 4: 101-106
- Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel.J Oncol Pharm Pract. 2018; 24: 153-155
- Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis.Ann Saudi Med. 2012; 32: 306-308
- Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: an unusual suspect.Am J Emerg Med. 2017; 35 (1384.e1-1384.e2)
- Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade.J Urol. 2004; 171: 1627
- Cancer statistics, 2018.CA Cancer J Clin. 2018; 68: 7-30
- Targeting DNA repair in prostate cancer.J Clin Oncol. 2018; 36: 1017-1019
- The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Cancer. 2017; 123: 3532-3539
- DNA-repair defects and olaparib in metastatic prostate cancer.N Engl J Med. 2015; 373: 1697-1708
- Aggressive variants of castration-resistant prostate cancer.Clin Cancer Res. 2014; 20: 2846-2850
- Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers.Clin Cancer Res. 2016; 22: 1520-1530
- Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline.J Clin Oncol. 2014; 32: 3436-3448
- DNA repair in prostate cancer: biology and clinical implications.Eur Urol. 2017; 71: 417-425
- Cancer risks among BRCA1 and BRCA2 mutation carriers.Br J Cancer. 2007; 96: 11-15
- Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol. 2013; 31: 1748-1757
- Exploiting DNA damage without repair: the activity of platinum chemotherapy in BRCA-mutated prostate cancers.Cancer. 2017; 123: 3441-3444
- Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.J Clin Oncol. 2009; 27: 5431-5438
- Platinum-based chemotherapy for variant castrate-resistant prostate cancer.Clin Cancer Res. 2013; 19: 3621-3630
- The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC).J Clin Oncol. 2017; 35: 5013
- Whole-exome sequencing of metastatic cancer and biomarkers of treatment response.JAMA Oncol. 2015; 1: 466
- ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Feb 29, 2000: Identifier NCT02598895: Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway, Nov 6, 2015.(Available at:)https://www.clinicaltrials.gov/ct2/show/study/NCT02598895Date accessed: July 24, 2018
- Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer.Int Urol Nephrol. 2016; 48: 1837-1838
- Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.South Med J. 2007; 100: 916-917
- Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer.Cancer Chemother Pharmacol. 2004; 54: 191-192
Article Info
Publication History
Published online: September 06, 2018
Accepted:
September 1,
2018
Received:
August 28,
2018
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
